Symtomax – Growing for health

Symtomax is a fast-growing company dedicated to the production, research, cultivation, processing and distribution of medicinal cannabis oil to pharmaceutical companies worldwide.

Symtomax lda is also in the process of developing the largest medical cannabis cultivation site in Europe, having received approval from INFARMED. Based in the Alentejo region of Portugal, the production and cultivation site will provide 95 hectares of rich, fertile soil, which is perfectly suited for harvesting high quality cannabis flower for their products.
Cannabinoids are one of over 100 naturally occurring compounds produced by the cannabis plant. Most will be familiar with the two of these; THC (or, delta-9-tetrahydrocannabinol) and CBD (cannabidiol). Currently, the European market for CBD is worth approximately €450m, which accounts for 31% of the global CBD oil market. To put things into perspective – Canada has a total of 326 hectares of licensed indoor and outdoor cultivation areas, with cannabis sales in Canada over 2020 expected to reach $2.8bn.

Symtomax’s mission is to demonstrate a strong regulatory commitment and compliance to international GMP standards while producing optimal yields of high-quality and consistent medical cannabis. Our aim is to build a global medical cannabis brand.

Infarmed is a Portuguese Government agency accountable to the Health Ministry, that evaluates, authorizes, regulates and controls human medicines as well as health products, namely, medical devices and cosmetics for the protection of Public Health.